Radio-guided surgery in neuroendocrine tumors

Journal of Surgical Oncology

Volumn 96, Issue 4, 2007, Pages 309-315

  Gulec, Seza A ^a,c   Baum, Richard ^b  

^a Goshen Health System Center for Cancer Care   (United States)

^b ZENTRALKLINIK BAD BERKA   (Germany)

^c Center for Cancer Care   (United States)

Author keywords

Neuroendocrine tumors; Somatostatin analog radiopharmacy; Somatostatin receptor scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ASPARAGINE OCTREOTIDE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE OCTREOTIDE GALLIUM 68; 5 HYDROXYTRYPTOPHAN; CALCITONIN ANTIBODY; CARBON 11; CARCINOEMBRYONIC ANTIBODY; CHOLECYSTOKININ B RECEPTOR; CHROMOGRANIN A ANTIBODY; COPPER 64; FLUORINE 18; GALLIUM 68; INDIUM 111; IODINE 125; IODINE 131; LUTETIUM; MONOCLONAL ANTIBODY; PENTAGASTRIN; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SUCCIMER TC 99M; UNCLASSIFIED DRUG; YTTRIUM 90; DIAGNOSTIC AGENT; DRUG DERIVATIVE; OCTREOTIDE; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; SDZ 215 811; SDZ 215-811; SOMATOSTATIN;

CANCER SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; KINETICS; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIO GUIDED SURGERY; REVIEW; SCINTIGRAPHY; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; TUMOR LOCALIZATION; COMPUTER ASSISTED SURGERY; METABOLISM; METHODOLOGY; PATHOLOGY; RADIOASSAY; RADIOIMMUNOASSAY; SCINTISCANNING;

GAMMA CAMERAS; HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PENTETIC ACID; RADIOIMMUNODETECTION; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SURGERY, COMPUTER-ASSISTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34848908032     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20868     Document Type: Review

References (64)

1. Reubi JC, Waser B: Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-793.
2. Reubi JC, Waser B: Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-793.
3. Reubi JC, Schar JC, Waser B, et al.: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282.
4. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
5. 111In-pentetreotide scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:BP140-BP147.
6. Gulec SA, Gaffga CM, Anthony CT, et al.: Antiangiogenic therapy with somatostatin receptor-mediated in situ radiation. Am Surg 2001;67:1068-1071.
7. Warner RR, O'dorisio TM: Radiolabeled peptides in diagnosis and tumor imaging: Clinical overview. Semin Nucl Med 2002;32:79-83.
8. Gulec SA, Drouant GJ, Fuselier J, et al.: Antitumor and antiangiogenic effects of somatostatin receptor-targeted in situ radiation with (111)In-DTPA-JIC 2DL. J Surg Res 2001;97:131-137.
9. Gulec SA, Gaffga CM, Anthony CT, et al.: Antiangiogenic therapy with somatostatin receptor-mediated in situ radiation. Am Surg 2001;67:1068-1071.
10. Rufini V, Calcagni ML, Baum RP: Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-247.
11. Kumar CC: Integrin alpha versus beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003;4:123-131.
12. Schillaci O, Spanu A, Scopinaro F, et al.: Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2003;44:359-368.
13. Reubi JC: Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004;80:51-56.
14. Jensen RT: Carcinoid and pancreatic endocrine tumors: Recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 2000;12:368-377.
15. Dorr U, Frank-Raue K, Raue F, et al.: The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. Nucl Med Commun 1993;14:439-445.
16. Gulec SA, Mountcastle TS, Frey D, et al.: Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg 2002;68:667-671.
17. Sutton R, Doran HE, Williams EM, et al.: Surgery for midgut carcinoid. Endocr Relat Cancer 2003;10:469-481.
18. Memon MA, Nelson H: Gastrointestinal carcinoid tumors: Current management strategies. Dis Colon Rectum 1997;40:1101-1118.
19. Gulec SA, Mountcastle TS, Frey D, et al.: Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg 2002;68:667-671.
20. Touzios JG, Kiely JM, Pitt SC, et al.: Neuroendocrine hepatic metastases: Does aggressive management improve survival? Ann Surg 2005;241:776-783.
21. Adams S, Baum RP, Hertel A, et al.: Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med 1998;39:1155-1160.
22. Schirmer WJ, O'dorisio TM, Schirmer TP, et al.: Intraoperative localization of neuroendocrine tumors with 125I-TYR(3)-octreotide and a hand-held gamma-detecting probe. Surgery 1993;114:745-751.
23. Woltering EA, Barrie R, O'dorisio TM, et al.: Detection of occult gastrinomas with iodine 125-labeled lanreotide and intraoperative gamma detection. Surgery 1994;116:1139-1146.
24. Adams S, Baum RP, Hertel A, et al.: Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med 1998;39:1155-1160.
25. Lebtahi R, Cadiot G, Sarda L, et al.: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-858.
26. Adams S, Baum RP, Hertel A, et al.: Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med 1998;39:1155-1160.
27. Ohrvall U, Westlin JE, Nilsson S, et al.: Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphy. Cancer 1997;80:2490-2494.
28. Kebebew E, Ituarte PH, Siperstein AE, et al.: Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-1148.
29. Gordon PR, Huvos AG, Strong EW: Medullary carcinoma of the thyroid gland. A clinicopathologic study of 40 cases. Cancer 1973;31:915-924.
30. Adams S, Baum RP, Hertel A, et al.: Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med 1998;39:1155-1160.
31. Schirmer WJ, O'dorisio TM, Schirmer TP, et al.: Intraoperative localization of neuroendocrine tumors with 125I-TYR(3)-octreotide and a hand-held gamma-detecting probe. Surgery 1993;114:745-751.
32. Gulec SA, Daghighian F, Essner R: PET-PROBE: Evaluation of technical performance and clinical utility in oncologic surgery. Ann Surg Oncol 2006; Ref Type: Abstract
33. Maecke HR, Behe M: New octreotide derivatives labelled with technetium-99m. J Nucl Med 1996;37 1144. Ref Type: Abstract
34. Rosch F, Herzog H, Stolz B, et al.: Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue. Eur J Nucl Med 1999;26:358-366.
35. Lewis JS, Lewis MR, Srinivasan A, et al.: Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 1999;42:1341-1347.
36. Hofmann M, Maecke H, Borner R, et al.: Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data. Eur J Nucl Med 2001;28:1751-1757.
37. 111In-DTPA-octreotide in the same patients: Biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999;40:762-767.
38. Otte A, Herrmann R, Heppeler A, et al.: Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439-1447.
39. Waldherr C, Pless M, Maecke HR, et al.: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-616.
40. Paganelli G, Zoboli S, Cremonesi M, et al.: Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:426-434.
41. Pashankar FD, O'Dorisio MS, Menda Y: MIBG and somatostatin receptor analogs in children: Current concepts on diagnostic and therapeutic use. J Nucl Med 2005;46:55S-61S.
42. Kaltsas GA, Papadogias D, Makras P, Grossman AB: Treatment of advanced neuroendocrine tumours with radiolabeled somatostatin analogues. Endocr Relat Cancer 2005;12:683-699.
43. Baum RP, Hofmann M: Nuklearmedizinische Diagnostik neuroendokriner Tumoren. Onkologe 2004;10:598-610.
44. Wild D, Macke HR, Waser B, et al.: 68Ga-DOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005;32:724.
45. Hofmann M, Maecke H, Borner R, et al.: Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data. Eur J Nucl Med 2001;28:1751-1757.
46. Wild D, Macke HR, Waser B, et al.: 68Ga-DOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005;32:724.
47. Wild D, Schmitt JS, Ginj M, et al.: DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-1347.
48. Lewis JS, Lewis MR, Srinivasan A, et al.: Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 1999;42:1341-1347.
49. Anderson CJ, Dehdashti F, Cutler PD, et al.: 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213-221.
50. Wester HJ, Schottelius M, Scheidhauer K, et al.: PET imaging of somatostatin receptors: Design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003;30:117-122.
51. Baum RP, Niesen A, Leonhardi J, et al.: Receptor PET/CT imaging of neuroendocrine tumors using the Ga-68 labelled, high affinity somatostatin analogue DOTA-1-Na13-octreotide (DOTANOC): Clinical results in 327 patients. Eur J Nucl Med Mol Imaging 2005;32 S54. Ref Type: Abstract
52. Baum RP, Schmucking M, Niesen A, et al.: Receptor-PET/CT of neuroendocrine tumors using the gallium-68 labelled somatostatin analog DOTA-NOC: First clinical results. Eur Radiol 2005;15 C-0409. Ref Type: Abstract
53. Henze M, Schuhmacher J, Hipp P, et al.: PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: First results in patients with meningiomas. J Nucl Med 2001;42:1053-1056.
54. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH: Radioiodinated metaiodobenzylguanidine: A review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545-559.
55. Oberg K, Eriksson B: Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005;19:265-276.
56. Orlefors H, Sundin A, Ahlstrom H, et al.: Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 1998;16:2534-2541.
57. Sundin A, Eriksson B, Bergstrom M, et al.: Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 2000;27:33-41.
58. Orlefors H, Sundin A, Garske U, et al.: Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-3400.
59. Eriksson B, Bergstrom M, Lilja A, et al.: Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol 1993;32:189-196.
60. Behr TM, Behe MP: Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002;32:97-109.
61. Behr TM, Becker W: Metabolic and receptor imaging of metastatic medullary thyroid cancer: Does anti-CEA and somatostatin-receptor scintigraphy allow for prognostic predictions? Eur J Nucl Med 1999;26:70-71.
62. Barbet J, Peltier P, Bardet S, et al.: Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 1998;39:1172-1178.
63. Siccardi AG, Paganelli G, Pontiroli AE, et al.: In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting. Eur J Nucl Med 1996;23:1455-1459.
64. Clarke SE, Lazarus CR, Wraight P, et al.: Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP - an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 1988;29:33-38.